Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methenamine mandelate is a small-molecule urinary antibacterial and antiseptic consisting of a 1:1 organic salt of methenamine and mandelic acid. After oral absorption and renal excretion, it becomes active in acidic urine: methenamine hydrolyzes to bactericidal formaldehyde, while mandelic acid contributes antibacterial activity and urine acidification. Its antibacterial effect is nonspecific and is used to suppress or eliminate bacteriuria associated with cystitis, pyelonephritis, chronic urinary tract infection, and infected residual urine in patients with neurologic bladder dysfunction. Activity depends on maintaining acidic urine, with maximal effectiveness at urinary pH 5.5 or lower. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=cc299e8a-cf9a-4dc6-b6e6-972141e59296))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methenamine mandelate.